title: Pharmacological profile and clinical efficacy of fully human anti-IL-17RA antibody Brodalumab (LUMICEF®Subcutaneous Injection 210 mg Syringe).
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Aono
authors.forename: Toru
authors.initials: T
authors.lastname: Amano
authors.forename: Hiroki
authors.initials: H
authors.lastname: Matsudo
authors.forename: Shota
authors.initials: S
authors.lastname: Hirose
authors.forename: Takuya
authors.initials: T
authors.lastname: Morishige
authors.forename: Natsuko
authors.initials: N
authors.lastname: Kikuta
authors.forename: Hiroki
authors.initials: H
authors.lastname: Okada
authors.forename: Noriko
authors.initials: N
authors.lastname: Hamaura
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D053722:Receptors, Interleukin-17 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C109985:IL17RA protein, human; D053722:Receptors, Interleukin-17; C571216:brodalumab